Literature DB >> 9029167

Highly metastatic hepatocellular carcinomas induced in male F344 rats treated with N-nitrosomorpholine in combination with other hepatocarcinogens show a high incidence of p53 gene mutations along with altered mRNA expression of tumor-related genes.

T Masui1, H Nakanishi, K Inada, T Imai, Y Mizoguchi, H Yada, M Futakuchi, T Shirai, M Tatematsu.   

Abstract

The carcinogenic and metastatic processes are thought to consist of a sequence of steps, and animal models featuring highly metastatic lesions are clearly necessary to allow analysis of the whole process of transformation from preneoplastic changes to high grade metastatic tumors, and to access effectiveness of therapeutic treatments of advanced cancers in vivo. The purpose of the present study was to establish a model and to screen for reported genetic alterations in induced lesions. In the present study, it was confirmed that lung metastasis of hepatocellular carcinomas (HCCs) induced in male F344 rats by N-nitrosomorpholine (NNM), given in the drinking water at a dose of 120 ppm for 24 weeks, was significantly enhanced by additional carcinogenic pretreatments and that a single i.p. injection of 100 mg/kg body weight N-diethylnitrosamine (DEN) alone was sufficient for that purpose. Molecular biological analyses of the induced lesions revealed point mutations in the p53 gene in 60.9% of HCCs, and elevated expression of mRNAs for p53, c-myc, c-fos, TGF-alpha, TGF-beta1, alpha-fetoprotein, GST-P, and GGT, and decreased mRNA expression of EGF and EGFR in HCCs when compared to controls. No obvious association of gene alterations with metastatic potential of primary tumors was found except for an increase in the incidence of p53 mutations. Since the process of metastasis is thought to be sequential and selective, further comparative analysis of metastatic and primary lesions should clarify the mechanisms involved in the multi-step process of metastasis.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9029167     DOI: 10.1016/s0304-3835(96)04543-0

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  7 in total

1.  Identify lymphatic metastasis-associated genes in mouse hepatocarcinoma cell lines using gene chip.

Authors:  Bo Song; Jian-Wu Tang; Bo Wang; Xiao-Nan Cui; Li Hou; Lu Sun; Li-Min Mao; Chun-Hui Zhou; Yue Du; Li-Hui Wang; Hua-Xin Wang; Ren-Shu Zheng; Lei Sun
Journal:  World J Gastroenterol       Date:  2005-03-14       Impact factor: 5.742

2.  Smad3 reduces susceptibility to hepatocarcinoma by sensitizing hepatocytes to apoptosis through downregulation of Bcl-2.

Authors:  Yu-An Yang; Gen-Mu Zhang; Lionel Feigenbaum; Ying E Zhang
Journal:  Cancer Cell       Date:  2006-06       Impact factor: 31.743

Review 3.  Hepatocellular carcinoma--cause, treatment and metastasis.

Authors:  Z Y Tang
Journal:  World J Gastroenterol       Date:  2001-08       Impact factor: 5.742

Review 4.  Metastatic human hepatocellular carcinoma models in nude mice and cell line with metastatic potential.

Authors:  Z Y Tang; F X Sun; J Tian; S L Ye; Y K Liu; K D Liu; Q Xue; J Chen; J L Xia; L X Qin; S L Sun; L Wang; J Zhou; Y Li; Z C Ma; X D Zhou; Z Q Wu; Z Y Lin; B H Yang
Journal:  World J Gastroenterol       Date:  2001-10       Impact factor: 5.742

5.  Potential role of p53 mutation in chemical hepatocarcinogenesis of rats.

Authors:  Wei-Guo Deng; Yan Fu; Yu-Lin Li; Toshihiro Sugiyama
Journal:  World J Gastroenterol       Date:  2004-01       Impact factor: 5.742

6.  c-Fos overexpression increases the proliferation of human hepatocytes by stabilizing nuclear Cyclin D1.

Authors:  Meryem Güller; Kahina Toualbi-Abed; Agnès Legrand; Laurence Michel; Alain Mauviel; Dominique Bernuau; Fanny Daniel
Journal:  World J Gastroenterol       Date:  2008-11-07       Impact factor: 5.742

7.  Establishment of an in vivo highly metastatic rat hepatocellular carcinoma model.

Authors:  M Futakuchi; M Hirose; T Ogiso; K Kato; M Sano; K Ogawa; T Shirai
Journal:  Jpn J Cancer Res       Date:  1999-11
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.